INS and type 2 diabetes mellitus: In a 4-week study in type 2 diabetes patients, weekly administration of up to 70 mg efruxifermin reduced triglycerides by 60–70%, non-HDL-cholesterol by about 35%, fasting insulin about 50%, and fasting glucose about 20% compared to baseline, while increasing HDL-cholesterol by 60% and adiponectin by about 95% (246).